MENLO PARK, Calif., May 1 /PRNewswire/ -- Apieron, Inc. (http://www.apieron.com) announced today that it has begun shipments of its Insight(TM) eNO System. Cleared by the FDA in March 2008, the Insight eNO System combines the accuracy, speed, and ease-of-use needed for the healthcare professional to provide office-based measurements of exhaled nitric oxide (eNO). Exhaled nitric oxide is a well established clinical indicator of airway inflammation and asthma control. With the use of eNO measurements, physicians can adjust inhaled corticosteroid therapy to optimize asthma control and avoid exacerbations or 'asthma attacks'.
The Insight eNO System's proprietary biosensor technology accurately measures eNO in parts per billion. Its single-use breath tubes are designed to be hygienic and convenient for the patient, and the disposable sensor generates a reading in less than a minute. Patient data can be stored and maintained in a unique format for trend analysis and printed for insurers' and patients' files. All of the System's functions are accessible through a small desktop monitor with a large color display and clinician-friendly interface.
"We showcased the Insight System at the March meeting of the American Academy of Allergy, Asthma and Immunology, and physicians responded enthusiastically to its graphical interface and its elegant technology," said Rich Lotti, President and CEO of Apieron, Inc. "As current methods for monitoring asthma airway inflammation are subjective, the Insight eNO System provides quantifiable information to increase therapeutic compliance. We believe this product will enable physicians to optimize medical therapy on an individualized basis, and therefore improve the standard of care for patients with asthma."
Sales and distribution of the Insight eNO System have been initiated with the introduction of an Apieron National Direct Sales Force in targeted major metropolitan regions.
About Apieron Inc.
Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was funded in 2003 to develop a simple-to-use, non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes such as eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.
SOURCE Apieron, Inc.
